Do you want to read an article? Please log in or register.
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
Genitourinary Cancer
Related content
COMMENTED
Genitourinary Cancer
Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Bladder Cancer
Kaufmann E, Aeppli S, Affentranger A, Arnold N, Arnold W, Aschwanden F, Balermpas P, Beyer J, Bieri U, Boormanns J, Cathomas R, Bari B, Dressler M, Engeler DS, Erdmann A, Gallina A, Gomez S, Guckenberger M, Herrmann T, Hermanns T, Lucca I, John H, Kessler TM, Klein J, Laouiti M, Lauffer D, Lerner SP, Mattei A, Müntener M, Nguyen D, Niederberger P, Papachristofilou A, Prause L, Putora PM, Reinhardt K, Salati E, Sèbe P, Shelan M, Sigg S, Strebel RT, Templeton AJ, Vogl U, Wettstein MS, Wyler S, Zihler D, Zilli T, Zwahlen D, Roth B, Fankhauser CD
doi: 10.1177/23523735251410823
Genitourinary Cancer
External validation of the Uromonitor®-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management
BJU Int
Rubio-Briones J, Guerrero Ramos F, Mercadé Sánchez A, Bezana Abadía I, Rodríguez RM, Alcaraz A, Miqueleiz Legaz M, Lozano F, Arrabal Martín M, Luis Cardo A, Gonzalo Rodríguez V, Caño Velasco J, Serrano Liesa M, Ferreiro Pareja C, Espílez Ortiz R, de González-Valcárcel de Torres I, Sánchez Zalabardo D, Esquinas C, Mengual L, Borque-Fernando A, Esteban Escaño LM, Palou Redorta J, Witjes F, Martínez Piñeiro L
doi: 10.1111/bju.70010
COMMENTED
Genitourinary Cancer
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
J Clin Oncol
Gore JL, Wolff EM, Nash MG, Comstock BA, Gilbert SM, Chang SS, Chisolm S, MacLean DB, Wright JL, Kates MR, Pohar KS, Guzzo TJ, Bivalacqua TJ, Nepple KG, Montgomery JS, Scarpato KR, Woldu SL, Master VA, Chen DYT, Mossanen M, Daneshmand S, O'Neil BB, Tyson MD, Westerman ME, Kamat AM, Mansour AM, Chamie K, Riggs SB, Kukreja JB, Modi PK, Garg T, Peyton CC, Nix JW, Dickstein R, Gadzinski AJ, Sankin A, Shore ND, Lane BR, Bassett JC, Patel S, Morris DS, Macleod LC, Lee EK, Ritch CR, Follmer KM, Lee JR, Kim SM, Kessler LG, Smith AB, CISTO Collaborative group
doi: 10.1200/JCO-25-01324
Further Publications
Nephrotoxicity Surveillance for Childhood and Young Adult Survivors of Cancer: Recommendations From the International Late Effects of Childhood Cancer Guideline Harmonization Group
J Clin Oncol
Kooijmans ECM, Mulder RL, Marks SD, Pavasovic V, Motwani SS, Walwyn T, Larkins NG, Kruseova J, Constine LS, Wallace WH, Green DM, Bökenkamp A, van der Pal HJH, van den Heuvel-Eibrink MM, Hjorth L, Andrés-Jensen L, Bardi E, van Dalen EC, Demoor-Goldschmidt C, Becktell K, Grönroos M, Kieran K, Mironova D, Terenziani M, Veening MA, Zieg J, Onder S, Onder AM, Routh JC, Thompson J, Hudson MM, Kremer LCM, Skinner R, Ehrhardt MJ
doi: 10.1200/JCO-24-02534
Genitourinary Cancer
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
N Engl J Med
Powles T, Kann AG, Castellano D, Gross-Goupil M, Nishiyama H, Bracarda S, Bjerggaard Jensen J, Makaroff L, Jiang S, Ku JH, Park SH, Reig Torras O, Ye D, Maruzzo M, Necchi A, Morales-Barrera R, Giunta EF, Lee JL, Tortora G, Ürün Y, Dolowy L, Erdem D, Pinto A, Grando F, Zou W, Assaf ZJ, Vuky J, Degaonkar V, Steinberg EE, Bellmunt J, Gschwend JE, IMvigor011 Investigators
doi: 10.1056/NEJMoa2511885
Genitourinary Cancer
The impact of treatment for muscle-invasive bladder cancer on health-related quality of life
BJU Int
Nuijens ST, van Hoogstraten LMC, Terpstra NB, Beeren I, Vrieling A, Wijnen EM, Meijer RP, Kiemeney LA, Witjes JA, Aben KKH
doi: 10.1111/bju.16736
Genitourinary Cancer
Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer
BJU Int
McElree IM, Steinberg RL, Hougen HY, Mott SL, Packiam VT, O'Donnell MA
doi: 10.1111/bju.70044
Genitourinary Cancer
Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy
BJU Int
Fazili A, Jazayeri SB, Rose KM, Guske C, Wen L, Durant A, Prunty M, Bukavina L, Tyson MD, Grass GD, Xu H, Spiess PE, Gilbert SM, Sexton WJ, Zemp L, Pessoa RR, Poch M, Lerner SP, Li R
doi: 10.1111/bju.16895
COMMENTED
Genitourinary Cancer
Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Eur Urol
Scilipoti P, Zaurito P, Longoni M, Colecchia M, Montorsi F, Salonia A, Mercinelli C, Maiorano B, Necchi A, Briganti A, Moschini M
doi: 10.1016/j.eururo.2025.12.022